Public Companies
Cybin recieves patent for CYB004
TORONTO – Cybin Inc. (NEO: CYBN) (NYSE American:CYBN), a biopharmaceutical company focused on progressing “Psychedelics to TherapeuticsTM”, announced…

TORONTO – Cybin Inc. (NEO: CYBN) (NYSE American:CYBN), a biopharmaceutical company focused on progressing “Psychedelics to TherapeuticsTM”, announced that the U.S. Patent and Trademark Office has granted U.S. patent 11,242,318 to the Company’s investigational deuterated dimethyltryptamine (DMT) compound CYB004. The allowed claims include a range of deuterated forms of DMT and 5-MeO-DMT. The patent, which is expected to expire in 2041 before consideration of any patent term extensions, covers composition of matter and protects the CYB004 drug substance as a putative new chemical entity.
CYB004 is Cybin’s lead investigational proprietary DMT compound. In preclinical studies, CYB004 has demonstrated potential efficacy at lower doses while also increasing the duration of drug effect providing a therapeutic profile that may alleviate the common negative experiences associated with classical DMT.
“From the outset, Cybin has focused on creating differentiated compounds that harness the potential efficacy of classical psychedelics, while addressing the known limitations necessary for these molecules to become approvable therapeutics. We are extremely pleased to receive a composition of matter patent for CYB004, adding strong protection for our growing intellectual property portfolio of psychedelic-based compounds, supporting and protecting the investments that we are making in our CYB004 program” said Doug Drysdale, Chief Executive Officer of Cybin. “This patent is both rewarding and timely as we prepare to initiate a pilot study for CYB004 in the third quarter of 2022 and work tirelessly to develop an important and alternative treatment option for the millions of people suffering from anxiety disorders.”
Cybin plans to submit a clinical trial application for a pilot study of CYB004 in the second quarter of calendar year 2022 and expects to initiate the pilot study in the third quarter of calendar year 2022.
The Company continues to pursue multiple opportunities to secure and support its patent position for research and development evaluating deuterated tryptamines for future psychedelic-based treatments for mental illnesses
Cybin is a leading ethical biopharmaceutical company, working with a network of world-class partners and internationally recognized scientists, on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues. Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, United Kingdom and Ireland. The Company is focused on progressing Psychedelics to Therapeutics by engineering proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health disorders. Patent filings described herein are held by Cybin IRL Limited, a wholly owned subsidiary of Cybin.
dmt dimethyltryptamine psychedelic therapeutics tryptamines anxiety psychedelics cybin research

-
Psilocybin17 hours ago
The Psychedelics Megatrend Is an Inevitable Boom
-
Public Companies16 hours ago
MindMed Expenses Rise As Company Files $100 Million Offering
-
Markets & Investing17 hours ago
Microdose’s Deal Board Helps Democratize Psychedelic Investing
-
Psilocybin18 hours ago
Optimi Health acquires catalog of psychedelic and functional mushroom genetics
-
Psilocybin12 hours ago
Can Ibogaine Treat Emotional Trauma?
-
Psilocybin12 hours ago
Journey Colab Looks to Mescaline for Treating Alcohol Use Disorder